摘要
程序性死亡受体1（PD-1）在人类多种免疫细胞和肿瘤细胞中广泛存在,当与程序性死亡受体1配体（PD-L1）结合后可耗竭T细胞致肿瘤免疫逃逸.体内外实验证实抑制PD-1与其配体结合,阻断下游信号通路可增强机体内源性抗肿瘤免疫效应.PD-1/PD-L1的表达不仅与食管癌患者临床分期及预后相关,还有可能成为临床生物标志物,而成为肿瘤免疫治疗的新靶点.文章就PD-1/PD-L1与食管癌的关系及相关治疗方案的最新研究进行综述.
Programmed death-1 （PD-1） occurs widely in a variety of human immune cells and tumor cells. When PD-1 is combined with programmed death-1 ligand （PD-L1）, T-lymphocyte will be exhausted eventually resulting in tumor immune escape. Experiments in vitro and in vivo have demonstrated that inhibiting the binding of PD-1 with PD-L1, and blocking downstream signaling pathways can enhance endogenous anti-neoplastic immune effects. The expression of PD-1/PD-L1 is related to the clinical stage and prognosis of esophageal cancer patients, which may become the clinical biomarkers, serving as a new target for cancer immunotherapy.This paper reviews the relationship between PD-1/PD-L1 and esophageal cancer as well as the related treatment progress.
出处
《肿瘤研究与临床》
CAS
2017年第11期776-780,共5页
Cancer Research and Clinic
基金
四川省卫生和计划生育委员会科研课题（17ZD006）
